Uncategorized Archives - Page 8 of 134

ThursdayAug 29, 2024 10:30 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will…

WednesdayAug 28, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients In MS, CNM-Au8 can work in conjunction with…

MondayAug 26, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

The company has released key corporate and business updates and Q2 2024 financial results Clinical trials for both Alzheimer’s and Parkinson’s studies yielded encouraging data for lead compound buntanetap Buntanetap in combination with GLP-1 agonist dulaglutide Trulicity(R) showed increased potential to synergistically enhance cognition The company has obtained a patent and begun manufacturing of a new crystalline form of buntanetap, with improved properties Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

TuesdayAug 20, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association…

WednesdayAug 14, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

Annovis Bio’s lead compound, buntanetap, shows significant enhanced cognitive benefits when combined with GLP-1 agonist dulaglutide in a mouse model Buntanetap targets neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases GLP-1 agonists, typically used for diabetes, weight loss, and heart conditions, have shown potential in addressing neuroinflammation and neurodegeneration The combination treatment results were compelling: While buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination restored and also enhanced cognitive function beyond levels seen in healthy controls Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced new preclinical data demonstrating lead compound buntanetap’s potential…

MondayAug 12, 2024 10:30 am

Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions

Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8 The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases,…

MondayAug 12, 2024 10:00 am

Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease

Parkinson’s disease is a progressive condition that affects an individual’s nervous system and the body parts controlled by the nerves. Scientifically speaking, the disease is brought on by neuronal damage caused by too much production of reactive oxygen species. Damage mainly affects neurons that produce dopamine, which plays a role in cognitive function and motor control. The condition usually gets worse over time, with the first symptom often being a tremor in the hands. Other symptoms include painful muscle contractions, tremors, and difficulty speaking. As the population globally grows older, the number of individuals suffering from Parkinson’s continues to increase.…

MondayAug 12, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap

U.S. Patent No. 12,042,482 specifically addresses traumatic brain injury (“TBI”) treatment with buntanetap, enhancing Annovis Bio’s portfolio that includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43 TBI is one of the major causes of death and disability in the US with annual death rate exceeding 70,000 Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions

Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease

Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search